P2Y12 antagonism -: Promises and challenges

被引：93

作者：

Michelson, Alan D. ^{[1
]}

机构：

[1] Univ Massachusetts, Sch Med, Ctr Platelet Funct Studies, Dept Pediat Med & Pathol, Worcester, MA 01655 USA

来源：

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2008年 / 28卷 / 03期

关键词：

platelets; clopidogrel; prasugrel; AZD6140; cangrelor;

D O I：

10.1161/ATVBAHA.107.160689

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The P2Y(12) antagonist clopidogrel has a well-established role as an antithrombotic agent in the settings of percutaneous coronary intervention and acute coronary syndromes. However, several challenges remain, including the relatively slow onset of action of clopidogrel and the phenomenon of clopidogrel response variability or "resistance". Novel P2Y(12) antagonists, including prasugrel, AZD6140, and cangrelor, have a faster onset of action, as well as more potent, and less variable, inhibition of platelet function ex vivo. Whether this promise will be translated into clinical benefit for patients will be determined by the results of ongoing phase 3 clinical trials.

引用

页码：S33 / S38

页数：6

共 53 条

[1] Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases [J].

Aleil, B ;

Ravanat, C ;

Cazenave, JP ;

Rochoux, G ;

Heitz, A ;

Gachet, C .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (01) :85-92

[2] High clopidogrel loading dose during coronary stenting:: effects on drug response and interindividual variability [J].

Angiolillo, DJ ;

Fernández-Ortiz, A ;

Bernardo, E ;

Ramírez, C ;

Sabaté, M ;

Bañuelos, C ;

Hernández-Antolín, R ;

Escaned, J ;

Moreno, R ;

Alfonso, F ;

Macaya, C .

EUROPEAN HEART JOURNAL, 2004, 25 (21) :1903-1910

[3] Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting [J].

Angiolillo, DJ ;

Fernandez-Ortiz, A ;

Bernardo, E ;

Ramírez, C ;

Barrera-Ramirez, C ;

Sabaté, M ;

Hernández, R ;

Moreno, R ;

Escaned, J ;

Alfonso, F ;

Bañuelos, C ;

Costa, MA ;

Bass, TA ;

Macaya, C .

THROMBOSIS RESEARCH, 2005, 115 (1-2) :101-108

[4] Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease - Results of the Optimizing antiPlatelet Therapy In diabetes MellitUS (OPTIMUS) study [J].

Angiolillo, Dominick J. ;

Shoemaker, Steven B. ;

Desai, Bhaloo ;

Yuan, Hang ;

Charlton, Ronald K. ;

Bernardo, Esther ;

Zenni, Martin M. ;

Guzman, Luis A. ;

Bass, Theodore A. ;

Costa, Marco A. .

CIRCULATION, 2007, 115 (06) :708-716

[5] Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel [J].

Angiolillo, Dominick J. ;

Fernandez-Ortiz, Antonio ;

Bernardo, Esther ;

Ramirez, Celia ;

Cavallari, Ugo ;

Trabetti, Elisabetta ;

Sabate, Manel ;

Hernandez, Rosana ;

Moreno, Raul ;

Escaned, Javier ;

Alfonso, Fernando ;

Banuelos, Camino ;

Costa, Marco A. ;

Bass, Theodore A. ;

Pignatti, Pier Franco ;

Macaya, Carlos .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (08) :1895-1900

[6] Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor:: A single ascending dose study in healthy humans [J].

Asai, Fumitoshi ;

Jakubowski, Joseph A. ;

Naganuma, Hideo ;

Brandt, John T. ;

Matsushima, Nobuko ;

Hirota, Takashi ;

Freestone, Stephen ;

Winters, Kenneth J. .

PLATELETS, 2006, 17 (04) :209-217

[7] Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events [J].

Bhatt, DL ;

Fox, KAA ;

Hacke, W ;

Berger, PB ;

Black, HR ;

Boden, WE ;

Cacoub, P ;

Cohen, EA ;

Creager, MA ;

Easton, JD ;

Flather, MD ;

Haffner, SM ;

Hamm, CW ;

Hankey, GJ ;

Johnston, SC ;

Mak, KH ;

Mas, JL ;

Montalescot, G ;

Pearson, TA ;

Steg, PG ;

Steinhubl, SR ;

Weber, MA ;

Brennan, DM ;

Fabry-Ribaudo, L ;

Booth, J ;

Topol, EJ ;

Frye, RL ;

Amarenco, P ;

Brass, LM ;

Buyse, M ;

Cohen, LS ;

DeMets, DL ;

Fuster, V ;

Hart, RG ;

Marler, JR ;

McCarthy, C ;

Schoemig, A ;

Lincoff, AM ;

Brener, SJ ;

Sila, CA ;

Albuquerque, A ;

Aroutiounov, G ;

Artemiev, D ;

Atkeson, BG ;

Bartel, T ;

Basart, DCG ;

Lima, AB ;

Belli, G ;

Bordalo e Sa, AL ;

Bosch, X .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (16) :1706-1717

[8] Increased risk in patients with high platelet amregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention - Is the current antiplatelet therapy adequate? [J].

Bliden, Kevin P. ;

DiChiara, Joseph ;

Tantry, Udaya S. ;

Bassi, Ashwani K. ;

Chaganti, Srivasavi K. ;

Gurbel, Paul A. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (06) :657-666

[9] Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events [J].

Bonello, L. ;

Paganelli, F. ;

Arpin-Bornet, M. ;

Auquier, P. ;

Sampol, J. ;

Dignat-George, F. ;

Barragan, P. ;

Camoin-Jau, L. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (08) :1630-1636

[10] A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation [J].

Brandt, John T. ;

Payne, Christopher D. ;

Wiviott, Stephen D. ;

Weerakkody, Govinda ;

Farid, Nagy A. ;

Small, David S. ;

Jaknbowski, Joseph A. ;

Naganuma, Hideo ;

Winters, Kenneth J. .

AMERICAN HEART JOURNAL, 2007, 153 (01) :66.e9-66.e16

← 1 2 3 4 5 6 →